Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Return on Sales (2016 - 2025)

Amicus Therapeutics' Return on Sales history spans 16 years, with the latest figure at 0.01% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 9.0% year-over-year to 0.01%, compared with a TTM value of 0.04% through Dec 2025, up 6.0%, and an annual FY2025 reading of 0.04%, up 6.0% over the prior year.
  • Return on Sales for Q4 2025 was 0.01% at Amicus Therapeutics, down from 0.1% in the prior quarter.
  • The five-year high for Return on Sales was 0.1% in Q3 2025, with the low at 1.08% in Q1 2022.
  • Average Return on Sales over 5 years is 0.42%, with a median of 0.42% recorded in 2024.
  • Year-over-year, Return on Sales skyrocketed 48bps in 2021 and then decreased -11bps in 2022.
  • Tracing FOLD's Return on Sales over 5 years: stood at 1.01% in 2021, then surged by 37bps to 0.63% in 2022, then soared by 54bps to 0.29% in 2023, then soared by 133bps to 0.1% in 2024, then plummeted by -91bps to 0.01% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Return on Sales are 0.01% (Q4 2025), 0.1% (Q3 2025), and 0.16% (Q2 2025).